---
title: 'Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology,
  price, beneficiaries, and spending'
date: '2024-01-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38244983/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240121170623&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Although partial orphans'' benefits, trials, and economics
  are more similar to non-than full orphans, they receive all of the ODA''s benefits
  and are swiftly extended to new indications; resulting in greater spending. A maximum
  ODA revenue/patient threshold could limit expenditure on partial ...'
disable_comments: true
---
CONCLUSIONS: Although partial orphans' benefits, trials, and economics are more similar to non-than full orphans, they receive all of the ODA's benefits and are swiftly extended to new indications; resulting in greater spending. A maximum ODA revenue/patient threshold could limit expenditure on partial ...